X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures

X4 Pharmaceuticals (NASDAQ:XFOR) has entered into a senior secured term loan agreement worth up to $150 million with K2 HealthVentures LLC, refinancing its existing debt facility and providing additional financial flexibility as the biotechnology company advances its clinical development and commercialisation plans.

The Boston-based company confirmed that an initial $80 million tranche was funded upon completion of the agreement.

Of that amount, X4 used funds to repay $75 million in outstanding principal, together with associated fees, under its previous loan arrangement.

The new financing replaces the earlier agreement and provides access to a potential additional $70 million, subject to lender approval and other specified conditions.

According to X4, the revised debt structure offers more favourable terms, including an extended interest-only repayment period and a maturity of 48 months.

The company intends to use the financing to support its corporate operations and development programmes, including preparations for a potential commercial launch of mavorixafor for chronic neutropenia.

New Loan Agreement Extends Repayment Flexibility

The financing arrangement with K2 HealthVentures is structured to provide X4 with immediate funding while preserving the possibility of accessing additional capital.

The initial $80 million payment was made available at closing, allowing the company to refinance its existing debt obligations.

The remaining $70 million is not automatically available and may be accessed only upon request, subject to approval from K2 HealthVentures and satisfaction of the relevant conditions.

The 48-month maturity term and longer interest-only period are intended to give X4 additional flexibility in managing its financing commitments while progressing its drug development activities.

The company has not disclosed all the financial terms of the facility, including the applicable interest rate, in the announcement.

Chief Financial Officer David Kirske said the revised financing arrangement supports X4’s business priorities.

“The new structure provides additional flexibility on more favorable terms and is aligned with our strategic priorities,” Kirske said.

The refinancing comes as the company continues investing in clinical development and evaluating opportunities to expand the commercial use of its lead drug.

Financing Supports Potential Mavorixafor Launch for Chronic Neutropenia

X4 plans to use the additional financial flexibility to support corporate activities, including the potential commercialisation of mavorixafor for chronic neutropenia.

Chronic neutropenia is characterised by persistently low levels of neutrophils, a type of white blood cell that plays an important role in the body’s defence against infections.

Mavorixafor is being evaluated as a potential treatment for chronic neutropenic disorders through the company’s ongoing clinical development programme.

The drug has received Fast Track designation from the US Food and Drug Administration (FDA) for the treatment of chronic neutropenia.

Fast Track designation is intended to facilitate the development and regulatory review of treatments for serious conditions where there is an unmet medical need.

However, the designation does not represent regulatory approval for the proposed indication.

Any potential commercial launch for chronic neutropenia will depend on the outcome of clinical development and the necessary regulatory decisions.

Phase 3 4WARD Trial Enrolment Expected to Finish in 2026

X4 also provided an update on its Phase 3 4WARD clinical trial, which is evaluating mavorixafor in patients with chronic neutropenic disorders.

The company expects to complete patient enrolment in the study by the end of 2026.

Topline results are anticipated during the first half of 2028, providing a future clinical milestone for the programme.

The trial is intended to generate additional evidence concerning the use of mavorixafor in chronic neutropenia.

Successful completion of the study and favourable results could support the company’s plans to pursue regulatory authorisation for the indication.

Nevertheless, the timing of any potential approval or commercial launch remains dependent on clinical outcomes and regulatory review.

The new financing arrangement provides X4 with additional funding flexibility as it works towards these development milestones.

Mavorixafor Already Approved for WHIM Syndrome

Although mavorixafor remains under investigation for chronic neutropenia, the medicine is already authorised in the United States and European Union for the treatment of WHIM syndrome under the brand name XOLREMDI.

WHIM syndrome is a rare immune disorder associated with abnormalities in white blood cell function and increased susceptibility to infections.

The existing approvals establish mavorixafor as a commercial product for WHIM syndrome, while X4 continues evaluating its potential use in additional conditions.

Expanding the drug’s approved indications could broaden its commercial opportunities, although any new indication requires supporting clinical evidence and regulatory authorisation.

X4 said further details of the financing agreement will be included in a filing with the US Securities and Exchange Commission.

The $150 million facility strengthens the company’s access to potential funding while it continues advancing the 4WARD trial and preparing for future regulatory and commercial milestones.

X4 Pharmaceuticals stock price